Overview

Update
Status
Acquired by on July 31, 2013
Total Equity Funding
$10M in 1 Round from 6 Investors
Headquarters:
Malvern, PA
Description:
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
Categories:
Therapeutics, Biotechnology, Medical
Website:
http://www.ceptaris.com

Company Details

Update
Founded:
2002
Aliases:
Yaupon Therapeutics
Contact:
610-975-9290
Employees:
11 - 50 | 9 in Crunchbase

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Funding Rounds (2) - $25M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2012$10M / Series D6
Feb, 2012$15M / Debt Financing2

Current Team (9)

Update

Board Members and Advisors (4)

Update

Offices/Locations (1)

Update
  • Office

    101 Lindenwood Drive

    Suite 400

    Malvern, PA 19355

    USA

Images (2)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos